William James Morris, BSc MSc MD FRCPC

Clinical Professor
Department of Surgery-Division of Radiation Oncology and Developmental Radiotherapeutics
University of British Columbia (UBC)

Active Staff – Radiation Oncologist
British Columbia Cancer Agency (BCCA) – Vancouver Centre *

Director of GU Radiation Oncology
(BCCA) – Vancouver Centre *

Principal Investigator for Developmental Brachytherapy
(BCCA) – Vancouver Centre *

Chair of the Provincial Prostate Brachytherapy Quality Assurance Committee
Active Staff, Vancouver Hospital and Health Sciences Centre

City: Vancouver
Hospital Authority: Provincial Health Services

Address: BCCA-VCC
600 West 10th Avenue
Vancouver, BC V5Z 4E6

Phone: 604.877.6000    Fax: 604.877.0505

Major Clinical Focus –
• Genito-Urinary cancers with a special focus on brachytherapy for prostate cancer
• Lymphomas


EDUCATION• Fellow of The Royal College of Physicians of Canada, Royal College of Physicians & Surgeons of Canada, Canada, 1990
• Doctor of Medicine, University of British Columbia, Canada, 1985
• Master of Science, University of Victoria, Canada 1980
• Bachelor of Science, University of Victoria, Canada 1973

POST GRADUATE AND FELLOWSHIP TRAINING
• Clinical research Fellow, Marie Curie Wing of the Mount Vernon Regional, Cancer Treatment Centre, Northwood, Middlesex, Great Britain, 1990-1991
• Chief Resident (Radiation Oncology), British Columbia Cancer Agency, Vancouver, British Columbia, Canada, 1989-1990
• Resident (Radiation Oncology), B.C. Cancer Agency, Vancouver British Columbia, Canada, 1987-1990
• Resident (Internal Medicine), Vancouver General Hospital, Vancouver, British Columbia, Canada, 1986-1987
• Licentiate of the Medical Council of Canada, Canada, 1986
• Rotating Intern, St. Paul’s Hospital, Vancouver, British Columbia, Canada, 1985-1986

Academic Interests and Activities, Clinical Activities
• instrumental in developing a highly productive multidisciplinary team with researchers from the Electrical and Computer Engineering department at UBC investigating advanced imaging systems to enable intraoperative prostate brachytherapy.
• prinicple investigator for a new (formed Oct 2011) multidisciplanary team investigating the role of focal brachytherapy. The team includes world-class researchers from the Vancouver Cancer Centre (of the BCCA), the BCCA Centre for Functional Imaging, the BC Cancer Research Centre, the UBC Prostate Centre, the Genome Sciences Centre, and the UBC Department of Electrical and Computer Engineering. We are seeking peer reviewed grant funding to combine novel imaging technology (MR elastograpy and PET scanning with new tracers), transperineal mapping biopsies and gene expression studies to determine who is suitable for this novel appraoch to prostate cancer.
• has performed ~ 1000 prostate brachytherapy procedures and ran the BC Provincial Prostate brachytherapy Program from its founding in Nov. 1997 to Sep. 2007 during which more than 2100 prostate implants were completed
• conducts a full time clinical practice in radiation oncology specializing in genito-urinary malignancies and lymphoproliferative diseases at the Vancouver Cancer Centre
• participates in the bedside and didactic teaching as well as the procedural and technical training of undergraduate medical students and oncology residents arriving from many Canadian and international universities
• supervises clinical research fellows, employed 6 undergraduate researchers, and overseen many resident research projects
• assists in the supervision of graduate students from the UBC faculties of Physics and Electrical/Computer Engineering and the Department of Medical Physics at BCCA whose work is supported by peer reviewed grants (as in Table 1) involved in advanced research into image guidance and robotics in therapeutic radiation


PUBLICATIONS ( Selected refereed publications 2010 to present )</span

1. Morris WJ, Keyes M, Spadinger I, Kwan W, Liu M, McKenzie M, Pai H, Pickles T, Tyldesley S. Population based 10 year oncologic outcomes after low dose rate brachytherapy for low- and intermediate-risk prostate cancer. Cancer (accepted for publication October 2012).
2. Tyldesley S, Peacock M, Morris WJ, So A, Kim-Sing C, Quirt J, Carter, M, and Pickles T. The need for and utilzation of Prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia. Canadian Urological Association Journal 2012; 6(2): 89-94.
3. Herbert C, Morris WJ, Hamm J, Lapointe V, McKenzie, Pickles T, Spadinger I, Keyes, M. Outcomes following Iodine 125 brachytherapy in Gleason 7 intermediate risk prostate cancer; a population based cohort study. Radiotherapy and Oncology; 2012; 103:228-232.
4. Herbert C, Morris WJ, Hamm J, Lapointe V, McKenzie M, Pickles T, Spadinger I, Keyes M. The effect of loose vs. stranded seeds on biochemical no evidence of disease in patients with carcinoma of the prostate treated with iodine-125 brachytherapy. Brachytherapy 2011; 10(6); 442-448
5. Keyes M, Spadinger I, Liu M, Pickles T, Pai H, Hayden A, Moravan V, Halperin R, McKenzie M, Kwan W, Agranovic A, Lapointe V, Morris WJ. Mitchell C C Liu. Rectal toxicity and rectal dosimetry in low-dose-rate iodine-125 permanent prostate implants: A long-term study in 1006 patients. Brachytherapy 2011; 11(3):199-208.
6. Chng N, Spadinger I, Morris WJ, Usmani N, Salcudean S. Prostate brachytherapy postimplant dosimetry: automatic plan reconstruction of stranded implants. Med Phys 2011;38(1):327-42.
7. Spadinger I, Morris WJ, Keyes M, Liu M, Shaffer R, Thompson A, Chng N, Woods R. Quadrant dosimetry as a predictor of biochemical relapse in 125I prostate brachytherapy. Brachytherapy 2011; 10(2): 87-97.
8. Usmani N, Chng N, Spadinger I, Morris WJ. Lack of significant intraprostatic migration of stranded iodine-125 sources in prostate brachytherapy implants. Brachytherapy 2010; 10 (4) 275-285
9. Pickles T, Morris WJ, Kattan MW, Yu C, Keyes M. Comparative 5-year outcomes of brachytherapy and surgery for prostate cancer. Brachytherapy 2010;10(1): 9-14.
10. Morris WJ, Halperin R, Spadinger I. Point: the relationship between postimplant dose metrics and biochemical no evidence of disease following low dose rate prostate brachytherapy: is there an elephant in the room? Brachytherapy 2010; 9(4):289-292.


* The British Columbia Cancer Agency (BCCA)-Vancouver Centre (VC) is the largest academic cancer centre for the BCCA, located in downtown Vancouver and treating about one third of the radiation oncology cancer patients in the Province of BC. Over 4360 cancer patients are seen each year in the radiation oncology department. There are 20 Radiation Oncology (RO) physician faculty with full disease site specialization and clinical programs of excellence, 2 General Practice (Internist) Oncology Physicians, 3 Clinical Fellows and 10 RO residents. The BCCA-Vancouver Centre also has 17 physicists and a graduate training program in physics, 15 nurses, >60 radiation therapists clerks, secretaries and many others within radiation oncology. General capabilities include 9 Linacs (including Truebeam), 1 cobalt, VMAT (first developed in the BCCA-VC), IMRT, SBRT, IGRT, HDR and LDR brachytherapy suites, and Protons (at the TRIUMF centre). The Vancouver Centre radiation oncology department conducts all levels of research (basic, translational, clinical, population), and is the main educational institution in BC for the training of graduate (residents) and undergraduate (medical) students. The interdisciplinary Radiation Oncology team is part of the even larger multidisciplinary and provincial teams.